Cargando…
Survey Reveals Patient and Health Care Provider Experiences and Challenges With the Use of High Doses of Basal Insulin
Type 2 diabetes is a chronic, progressive disease, and its management results in a high emotional burden on patients. Eventually many patients require and can benefit from the use of insulin. This article reports results of a survey of patients and health care providers regarding their experiences o...
Autores principales: | Goldman, Jennifer D., Angueira-Serrano, Eugenio, Gonzalez, Jeffrey S., Pang, Christianne, Tait, Jacqueline, Edelman, Steven |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Diabetes Association
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10115766/ https://www.ncbi.nlm.nih.gov/pubmed/37092159 http://dx.doi.org/10.2337/cd22-0062 |
Ejemplares similares
-
Real-World Persistence, Adherence, Hypoglycemia, and Health Care Resource Utilization in People With Type 2 Diabetes Who Continued With the Second-Generation Basal Insulin Analog Insulin Glargine 300 Units/mL or Switched to a First-Generation Basal Insulin (Insulin Glargine 100 Units/mL or Detemir 100)
por: Edelman, Steven, et al.
Publicado: (2023) -
Breaking Barriers With Basal Insulin Biosimilars in Type 2 Diabetes
por: Heller, Simon, et al.
Publicado: (2023) -
Initiation of iGlarLixi Versus Basal-Bolus Insulin in Adults With Type 2 Diabetes Advancing From Basal Insulin Therapy: The SoliComplex Real-World Study
por: Pantalone, Kevin M., et al.
Publicado: (2023) -
Therapeutic Options for the Management of Postprandial Glucose in Patients With Type 2 Diabetes on Basal Insulin
por: Hinnen, Debbie A.
Publicado: (2015) -
Short-Term Outcomes for Veterans Receiving Basal Insulin, Metformin, and a Sulfonylurea Who Are Started on a Third Noninsulin Agent Versus Prandial Insulin
por: Santeusanio, Andrew D., et al.
Publicado: (2018)